I would remove penicillin and state antibiotics as different antibiotics can also be used (as you mention above). The guidance states that ROUTINE screening should not be offered, however women with risk factors should be screened. This should be clearer. RCOG change is because of increased infection risk in premature infants, this should be clarified. I think GBSS could be mentioned as patient advocates. Prospective data from the CDC also demonstrates reduced rates over time since implementation with accelerated reduction with each new policy change (ABC data). Methods I do not follow the logic as to why women with risk factors would not be screened. Do you mean only women with incidental carriage detected (who would already have been screened) and women with a previously affected baby only? As RCOG have now included Premature labour, have you considered this in a secondary analysis? Doe sit change your figures? Screening can be offered at any point and most women will receive screening in the USA by 35 weeks. Consensus approach -so if a study was poorer quality but from the UK was it prefered to an RCT from another setting? Why was only severe disability used? Moderate disability but ability to enter mainstream school has high economic burden as well. Although your additional numbers from treatment are small these represent approximately 25% of all disease cases (52-57 additional cases (so 122-127 total from a cohort of 421 cases overall). This is quite a good result is it not? How many overall deaths are estimated? Again, three deaths may not sound many but if risk-based alone only identified 1 then screening will be more effective. It could be argued that even 1 death is too many. In your discussion you say 6 deaths so additional screening would prevent 50% of these deaths? This should be clarified. Discussion -you do not mention the screening test sensitivity in your intro, should be included there or in the discussion to add context. Second paragraph, do you mean that because of the transcient nature of GBS carriage a woman may be negative at 37 weeks but aquire GBS at delivery? This section could be clearer. Kwatra et al discuss median duration of carriage during pregnancy. Where does your transition data come from? Needs a reference Your arguement that women with a known infant with GBS or who incidentally screened would not benefit from screening does not totally make sense. We know that only 30% of women who have term infants with GBS disease had risk factors so this does not add up. see O'Sullivan et al. I cannot find the PPV of screening in the reference you cite. Is it not the NPV that is important in a screening test? As you suggest, the current screening test is not good enough to predict infants at risk, but would PCR be better? There are reports from the USA that do not demonstrate long term effects of IAP use. The last Cochrane review states low quality evidence for their conclusions -how has your review improved on this? What robust evidence sources? What parameters had no data? The limitations section needs to be expanded to include uncertainties about estimates and use of data.
You mention that consensus was achieved on the model -what about your conclusions?
In your table of evidence, it appears that the RF indicating IAP are all based on expert opinion, is that correct? This should be clearly highlighted in your limitations. O'Sullivan et al has more recent data on EOGBS that would be useful to update (you cite it in your introduction and the group are part of your expert panel. Why did you not use these data?)
REVIEWER
G Gopal Rao Northwick Park Hospital UK Member of Group B Streptococcus Support (GBSS) Medical Advisory council REVIEW RETURNED 10-Jun-2018
GENERAL COMMENTS
The paper addresses an important controversial area in the prevention and management of neonatal sepsis in the UK. This is paper based on a modelling study commissioned by the National Screening Committee (England) to estimate the potential impact of addition of culture-based screening for Group B Streptococcus (GBS) in pregnancy to the existing risk-based prevention policy in the UK. The authors aimed to establish agreement amongst a multi-disciplinary group of key stakeholders on model input parameters.
In my opinion there are three main aspects that determine the outcome and credibility of modelling in such studies. Assumptions that are used to build the model, the methodology used and and validation of the model.
Assumptions:
The authors of the paper have been selective in their reference to studies used build the model. 1. The model has ignored a major comprehensive survey (prospective enhanced surveillance) undertaken by the British Paediatric Surveillance Unit (BPSU. The findings of this survey are likely to be more reliable than the figures used based on the Public Health England survey. The latest BPSU Study data for the UK & ROI in 2014/5,, showed 475 EOGBS cases (0.54/1,000 LB), a substantial increase from the 2000/1 BPSU results of only 377 EOGBS cases (0.48/1,000 LB). At the time of introduction of risked based strategy for IAP in 2003, it was predicted that the rates would fall by 50%. Despite the implementation of risk based IAP in the UK, for over 15 years, the rates of EOGBS have steadily risen let alone fall! I cannot understand how a modelling can ignore the 'real life data'. The survey concludes, "Since the national surveillance of 2000-2001 there has been a significant increase in the incidence of invasive GBS disease in all five British Isles countries. There has been a proportionately greater increase in the incidence of LO disease; however the increase was also evident for EO incidence, despite the presence of national prevention guidelines. New strategies for preventing GBS in this age group are urgently required." (O'Sullivan C , Lamagni T , Efstratiou A , et al . Group B streptococcal (GBS) disease in UK and irish infants younger than 90 days, 2014-2015. Arch Dis Child 2016;101:A2) 2. While the authors have referred to the new RCOG guidelines that appeared in 2017, they have also failed to acknowledge two observational studies of screening were published in the BMJ Open in 2017, which are the only published reports of a screening programme, its design, implementation and outcome. The first paper, reports a substantial fall in EOGBS rates following GBS screening and intrapartum antimicrobial prophylaxis of the carriers of GBS. The paper also provides rates of GBS colonization in different ethnic groups. The second study reported on rise in rates in early onset GBS infection after cessation of the screening programme. While RCTs are considered as the gold standard, to ignore these observational studies (albeit in a single centre) in preference to systematic reviews and metanalysis of trials not necessarily undertaken in the UK, is to sacrifice the good at the alter of the seemingly perfect. (Gopal 
Validation
The real data from the BPSU does not show the predicted fall from the risk based strategy described in the modelling. On the contrary, it shows a rise despite risk based strategy being recommended for 15 years in the UK. This suggests either the guidelines are incorrect, the implementation is poor or the modelling is incorrect.
Overall, I get the impression that authors have not been sufficiently objective. They have been selective in the development of the modelling and the narrative, in favour of the currently advocated risk based IAP.
1. At present, the methodology of the modelling process is difficult to understand and follow through. 2. The modelling estimates of the outcomes are heavily dependent on the estimates of the parameters. This is acknowledged by the researchers, and a limited 'sensitivity analysis' is carried out by considering a range of values for four of the parameters. However, it would be useful to extend this to some of the more influential parameters in the model, and to report how this might affect the results.
3. The results are presented in Figure 1 . However , I do not find this very easy to interpret. The main results in the differences between the two scenarios are concentrated in the bottom part of the Figure. Perhaps, a simple table of the main findings could be presented?
4. There are a few pieces of information presented in the paper which perhaps could be reworded for clarity. For example, on Page 4 there is the statement, "In the UK, the EOGBS-mortality rate in term newborns is……". In fact this refers to the mortality rate in term babies with EOGBS.
REVIEWER

Katharine Correia Department of Mathematics and Statistics Amherst College USA REVIEW RETURNED
24-Jul-2018
GENERAL COMMENTS
This paper reports on a modelling study designed to estimate the potential impact of adding culture-based screening for Group B Streptococcus in pregnancy to the existing risk-based prevention policy in the UK. The paper is very well-written. The goal of the paper is well-defined, and the methods are explained clearly.
Major comments 1. Page 6, Line 9: I was unaware that Microsoft Excel has the capabilities needed to perform a modelling study. Is this done using a point-and-click process, or is there reproducible code which could be provided? It would be helpful if code could be provided in the Supplementary material, such that other researchers could replicate the study, or reproduce the model to extend upon this research. Table 2 , the rate of maternal intrapartum infection in term deliveries is specified to be 2.1%. Is this a typo, or am I misunderstanding what rate this corresponds to in the Daniels paper?
Minor comments
• Page 4, line 17: To be consistent with the rest of the paper, remove comma from 1,000 (or add comma to 1,000 in other instances in paper)
• Page 4, lines 24-25: When I first read this sentence, I thought it implied 6-10% of term newborns died from EOGBS. This obviously isn't the case. Is it that 6-10% of term newborns with EOGBS die? Or that 6-10% of newborn deaths are due to EOGBS? Please clarify.
• Page 9, second paragraph: It would be helpful to the reader if the estimated number of EOGBS deaths and severe disability cases were added to the text. This information is in Figure 1 , but since the number of deaths and severe disability prevented is written in the paragraph text below, it would be helpful to have the baseline numbers in the above text as well for reference.
• Figure 1 is blurry and difficult to read. Please make clearer.
• Table 4 , Page 19, Line 3: What does RR stand for? I do not see this defined anywhere in the paper. I assume RR 0.17 implies, for instance, that the risk of EOGBS in women receiving IAP is 0.17 times the risk in women not receiving IAP. Please clarify.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1, K Le Doare Comment
Thank you for your review of this important topic. I have a number of concerns about the content and generalisability of the paper that should be addressed before it is published.
Thank you for commenting on the manuscript.
I note that you do not include your expert panel in the author group, although you use their data within the model. Was the manuscript discussed with them and have they agreed to the publication of the data in this format?
Response
The expert group have seen and commented on a report of the project. The aim of publishing the work of the expert group was discussed and agreed during the meetings of the group. The manuscript itself has not been seen by the group.
The manuscript is a shorter version of a project report which was circulated to the expert group for comments.
The manuscript has not been reviewed by the expert group. This is now stated in the author contributions.
1. Abstract -as your input data was extremely limited, I would suggest that the conclusions be rephrased to demonstrate the considerable uncertainty of your estimates.
A sentence has been added to emphasise this.
A risk-based screening policy in the UK has not reduced EOGBS disease whilst screening based policies in other countries have demonstrated considerable declines. It would be useful to discuss what alternatives might be available within the main body of the manuscript.
The most recent BPSU / PHE enhanced surveillance study reported a higher rate of EOGBS than the previous study undertaken in 2000 -2001 . Personal communication from the study team highlighted a number of possible factors which may explain this. The impact of the risk based strategy has not been formally evaluated.
The expert group was brought together to discuss the impact of culture based screening in late pregnancy when added to risk based management. This strategy is the focus of the debate in the UK. In the course of its deliberations the expert group rejected the idea of modelling alternatives such as an intrapartum screening strategy. To try to keep to the word limit this has not been included in the manuscript.
Design: you could describe your model more completely in the abstract Response A fuller description has been added to the abstract.
Strengths and limitations: it would be useful to describe your hierachy of evidence here. It would be more productive to list all strengths and then the limitations.
As described in the methods section where possible higher quality evidence such as systematic reviews (and RCTs as appropriate) were used as data sources, although these were not always available. The hierarchy applied was the traditional EBM hierarchy, with systematic reviews at the top of the hierarchy, followed by RCTs, then comparative observational studies (cohort studies, then case-control studies), then uncontrolled observational studies (case series, then case reports). This was applied in a pragmatic fashion, as for a lot of the data inputs required, not all study designs would have been relevant/appropriate. For example, one would not expect RCTs looking at e.g. the proportion of women with no antenatal risk factors for GBS etc. Therefore for these inputs we aimed to use recent observational evidence from a UK population where possible.
We have re-worded the statement around evidence as indicated.
Backgound: GBS is also the leading cause of neonatal meningitis.
This has been added to the manuscript.
Reference 5 does not provide the data you quote, where did this information come from. I note this is approx a 20% increase which is quite significant. Has case fatality increased as well? Apologies, this should have been reference 7 and has been amended.
The comment itself relates to the rate of EOGBS reported by the recent BPSU / PHE enhanced surveillance study. This is discussed in reference 6. Reference 6 is the UK NSC review of screening from 2016. This was undertaken by Warwick University Medical School. https://legacyscreening.phe.org.uk/groupbstreptococcus Pages 14 and 34 report data from the BPSU / PHE enhanced surveillance study. Data were kindly supplied by the study team to inform the review.
The BPSU / PHE study reported that case -fatality rate was lower than the previous study (5.2% vs 9.6%).
The Lamagni paper cited includes isolates from all disease ages, it would be useful to extract the data pertinent to the neonatal EOGBS population from this maunscript.
This comment refers to the manuscript's statement relating to patterns of GBS resistance to antibiotics, in particular to clindamycin. We were unable to identify age related data on resistance to clindamycin from the publication or from the PHE Health Protection Report for 2016.
The sentence has been amended to reflect the reviewer's concern.
An additional reference to the PHE Health Protection Report 2016 has also been added.
This comments that the available data on clindamycin resistance 'support recently re-issued guidance by the Royal College of Obstetricians and Gynaecologists regarding the prevention of early-onset neonatal GBS disease, specifically that clindamycin can no longer be recommended for treatment due to the rate of resistance.'
The reference is 'Laboratory surveillance of pyogenic and non-pyogenic streptococcal bacteraemia in England, Wales and Northern Ireland: 2016 Health Protection Report Volume 11 Number 41, p14'.
Reference 9 is a cost-effectiveness analysis and gives QALY data rather than disability data. Data were reported to be insufficient to estimate outcomes in babies affected by EOGBS without meningitis. For GBS meningitis, the reported estimates were comparable to those in the Colbourn et al systematic review. In the latter systematic review outcomes from EO and LOGBS meningitis were reported separately.
The paper reflects the modelling conducted using inputs agreed through discussions with the expert group, and as such it would be inappropriate to retrospectively change data inputs.
Antenatal screening -the PHE methods include enrichment broth and selective culture (you could reference these).
A reference to this has been added.
The issue with antenatal screening is that it identifies a snapshot of women currently colonised but tells us nothing about how long they have been colonised for, nor what the risk to the infant is of this colonisation. This should be clearer here.
The themes of changing colonisation status and risk of EOGBS in women colonised with GBS at 35-37 weeks gestation are discussed throughout the manuscript.
In the early part of the manuscript it was necessary to emphasise the overall rationale for the current screening policy recommendation. This is that there was insufficient evidence on the benefits and harms of screening.
I would remove penicillin and state antibiotics as different antibiotics can also be used (as you mention above).
This comment refers to the sentence 'The purpose of screening is to identify a group of women who are eligible for intravenous intrapartum antibiotic prophylaxis (IAP) using penicillin as a means of preventing early onset GBS (EOGBS) disease.'
The sentence has been amended to emphasise that penicillin is the mainstay of EOGBS prevention.
The guidance states that ROUTINE screening should not be offered, however women with risk factors should be screened. This should be clearer. This comment appears to refer to the section of the manuscript headed 'Antenatal Screening'.
This comment refers to the section of the manuscript headed 'Antenatal Screening'.
The term routine has been added to the sentence.
However, in the model a distinction is made between between 'screening' which is defined as culture based testing at 35-37 weeks gestation in all women who are not identified as being at risk and a risk factor based approach which is described as 'clinical practice' in this section.
The aim of the modelling exercise was to explore the impact of 'screening' when added to 'clinical practice'. This point ends the section headed 'Antenatal Screening'.
This theme is returned to throughout the manuscript.
RCOG change is because of increased infection risk in premature infants, this should be clarified.
This comment refers to the sentence 'Since the completion of the modelling exercise, the RCOG has updated its guideline on GBS.7 The main change is that they now recommend offering GBS IAP to all women in confirmed preterm labour.'
Response A further sentence has been added.
I think GBSS could be mentioned as patient advocates.
An amendment to the manuscript has been to emphasise the role of GBSS in the campaign for screening.
Prospective data from the CDC also demonstrates reduced rates over time since implementation with accelerated reduction with each new policy change (ABC data).
These reports have now been included in the manuscript.
I do not follow the logic as to why women with risk factors would not be screened. Do you mean only women with incidental carriage detected (who would already have been screened) and women with a previously affected baby only?
This comment refers to the description of the two modelled scenarios in the second paragraph of page 6. In particular:
'This meant that women with known risk factors who should already be offered IAP under UK guidelines continued to be offered IAP without screening, and women without these risk factors were offered screening. Women giving birth pre-term (i.e. before 37 weeks) were assumed to not receive screening, due to the timing of the screening test (at 36 weeks).'
In the model 'screening' refers only to culture based testing at 36 weeks' gestation. Internationally, guidelines frequently recommend that screening should not be offered to women who are identified as being at risk before this point, as they would automatically be offered IAP -screening would not alter this decision. This is essentially the approach recommended by the CDC 2010 guidelines, where a previous infant with invasive GBS disease or GBS bacteriuria in the current pregnancy are both indications for receiving IAP (independent of GBS screening result). This was the assumption used in the model.
We hope this explains the query.
As RCOG have now included Premature labour, have you considered this in a secondary analysis?
The paper reflects the modelling conducted using inputs agreed through discussions with the expert group, and as such it would be inappropriate to retrospectively change model structure or data inputs.
In addition, because screening is offered at 37 weeks, women who give birth prematurely (before 37 weeks) would not be screened. Therefore the treatment of these women would be the same in both scenarios in the model, and inclusion of IAP for these women would not change the impact of screening.
The modelling work was completed before the revised RCOG guideline. It is mentioned in the manuscript to clarify that the previous guideline defined the risk factors which should prompt the offer IAP and which formed the basis of the modelled risk based strategy.
No analysis has been made of the impact of offering IAP to all women in established preterm labour. This has been added to the limitations of the project.
This is now referred to in the strengths and limitations section.
Screening can be offered at any point and most women will receive screening in the USA by 35 weeks. Internationally, guidelines recommend that culture based screening should be undertaken between 35 -37 weeks gestation.
The model assumed screening would be undertaken at 36 weeks.
Consensus approach -so if a study was poorer quality but from the UK was it prefered to an RCT from another setting?
Response If two such alternative sources of data were identified, both sources and their pros and cons were presented to the expert group, who debated the values and decided on which best matched the parameter required, and was more likely to reflect the UK setting.
Most model inputs would not be the sort of data which would have been obtained from RCTs (e.g. a lot of the inputs pertained to the rates of certain clinical characteristics among pregnant women), with the exception of the effect of antibiotic treatment. In such cases, if there were data from the UK (ideally from national data sources), these were preferred as these would be most representative of the UK.
We hope this clarifies the approach taken Why was only severe disability used? Moderate disability but ability to enter mainstream school has high economic burden as well.
The expert group discussed this. It was agreed that, as an attempt to develop a shared set of assumptions in a controversial area, the model should focus on a limited number of outcomes.
The data on moderate to mild disability was considered less reliable than that on severe disability. See the Colbourn et al systematic review.
This has been added to the limitations section of the manuscript.
Although your additional numbers from treatment are small these represent approximately 25% of all disease cases (52-57 additional cases (so 122-127 total from a cohort of 421 cases overall). This is quite a good result is it not?
The manuscript has been amended.
However the discussion should be balanced with an estimate of the additional number of women who would need to be treated with IAP to prevent an affected baby.
This is a key discussion point, as this is rarely discussed in relation to screening to prevent EOGBS and was one of the reasons the modelling work was undertaken through an expert group including all perspectives in the debate.
How many overall deaths are estimated? Again, three deaths may not sound many but if risk-based alone only identified 1 then screening will be more effective. It could be argued that even 1 death is too many. In your discussion you say 6 deaths so additional screening would prevent 50% of these deaths? This should be clarified.
We agree that ideally there would be no deaths due to EOGBS. However, any reduction in EOGBS deaths needs to be weighed up against the steps that need to be taken in order to achieve this, and the wider impact of these. Publication of the manuscript may generate discussion of this.
Second paragraph, do you mean that because of the transcient nature of GBS carriage a woman may be negative at 37 weeks but aquire GBS at delivery? This section could be clearer. Kwatra et al discuss median duration of carriage during pregnancy
The comment refers to the sentences 'In addition, the uncertain false negative rate from the screening test combined with natural transition of GBS carriage status between screening and labour mean that not all women carrying GBS at labour would be treated. The model estimated that between 20,916 and 30,726 women who screened negative at 36 weeks gestation would be GBS positive at delivery.'
Essentially, women tested for GBS at 36 weeks and again during labour may not have the same GBS colonisation status. This may be due to two factors: (1) inaccuracy of the test (either at 36 weeks or at the time of labour), (2) true transition in status between the two points. It is not possible to differentiate between these two possibilities, so we have just utilised "transition rates" without trying to dissect out test performance from true transition.
Therefore the reviewer's interpretation is in part correct.
We have reviewed and amended the paragraph.
Where does your transition data come from? Needs a reference
The initial range of colonisation transition rates we intended to use were based on the figures from various sources from the literature such as the Valkenburg systematic review. However, using the planned pairs of transition rates resulted in the model being "unbalanced" when these estimates from the literature were used, so these numbers needed to be adjusted. This was discussed with and agreed by the expert panel. This is explained in more detail below.
The starting assumption was that there would be a colonisation rate of 22% at any given point in pregnancy. When the transition rates from the literature were applied in the screening scenario it resulted in more than 22% of women being carriers at term. Because the transition rates are only applied in the screening scenario (because this is the only scenario in which GBS status is known at both points), in turn this resulted in a higher number of EOGBS cases in the risk factor plus screening scenario compared to the risk factor alone scenario. This is clearly not accurate, so the transition rate inputs had to be balanced in such a way that the overall colonisation rate did not differ at screening and at term.
Two combinations of transition rate values were used to produce two base case scenarios in which the overall colonisation rate at term remained at 22% but in which the transition rates from positive to negative and vice versa varied. This was discussed with the expert group and the approach was accepted. The two combinations of colonisation transition values were also agreed by the expert group.
This issue is discussed in the manuscript and table 5 identifies the source as expert opinion to reflect the fact that the rates needed to be adjusted (and therefore do not reflect a single source) but the main references on which some of the figures were selected have been added.
Your arguement that women with a known infant with GBS or who incidentally screened would not benefit from screening does not totally make sense. We know that only 30% of women who have term infants with GBS disease had risk factors so this does not add up. see O'Sullivan et al.
The screening strategy assumes that women identified as being at risk prior to 36 weeks would be offered IAP, without the need for culture based screening. This is a frequent feature of guidelines where screening is recommended.
Therefore these "at risk" groups could not be said to benefit from screening as they are offered IAP without the need for screening (ie their treatment would not change whether screening is in place or not).
I cannot find the PPV of screening in the reference you cite. Is it not the NPV that is important in a screening test?
This can be found on p56 of the UK NSC review of screening undertaken by Warwick University Medical School.
'Therefore, even a test assumed to be perfect at detecting maternal colonisation in the third trimester of pregnancy, would have a PPV of just 0.2% (350/150,806) for detecting EOGBS in the newborn child.'
Both NPV and PPV are important. In the context of screening for maternal GBS carriage, in the absence of a risk refinement strategy following the screening test the PPV focuses attention on the rate of overdiagnosis and overtreatment.
As you suggest, the current screening test is not good enough to predict infants at risk, but would PCR be better?
The predictive value of PCR was not explored in the modelling project. The debate in the UK has focused on culture based screening at 35 -37 weeks. We sought to address some of the issues raised by this strategy.
The last Cochrane review states low quality evidence for their conclusions -how has your review improved on this? What robust evidence sources? What parameters had no data? The limitations section needs to be expanded to include uncertainties about estimates and use of data.
This comment refers to:
'…wherever possible input parameters were based on robust evidence sources, including national guidance, national data sources, systematic reviews and RCTs.
For each parameter we aimed to utilise the best available evidence that would be representative of the UK. So, although the Cochrane review states that the existing evidence is of low quality, the review is the most robust evidence available. We have changed the word "robust" to "best available" to clarify.
Parameters with no direct data source, or where the existing data were decided not to be good enough, or relevant enough to the UK, were populated through expert opinion. These are listed in the tables.
The section has been amended to incorporate these points.
You mention that consensus was achieved on the model -what about your conclusions? Response
The results of the model were discussed at a meeting of the expert group and, following that, a draft report was circulated for comments. The report was amended in response to the comments. The amended version forms the basis of the manuscript.
Responses indicated that the outputs of the model were consistent with the inputs identified by the group. Some members requested that the discussion take account of the context in which screening would take place. For example the Antimicrobial Resistance Strategy and the Maternity Services Review.
In particular, representatives of GBSS were concerned that the results of the modelled risk based scenario did not reflect those of the enhanced surveillance study which showed an overall increase of EOGBS when compared to an earlier study. The available results reported a higher rate of EOGBS in term women . The rate of EOGBS in term babies was 0.41 / 1000 live births. This compares to 0.3 / 1000 from the previous enhanced surveillance study and 0.38 / 1000 live births from a later systematic review of UK data (Colbourn et al 2007) .
In addition a higher proportion of term babies affected by EOGBS were born to women without risk factors which would prompt IAP in UK guidance.
The concern was that overestimating the preventive impact in the risk groups would result in underestimating that of screening. In turn, this would result in overestimating the additional number of women treated to prevent EOGBS as a consequence of screening in late pregnancy.
GBSS therefore did not agree with the model outputs and requested that the modelling project should be revisited.
However:
• Detailed results of the enhanced surveillance study were not available at the time of the above discussion.
• The estimate of women treated per EOGBS case prevented in the screening scenario was not dependent on the estimate in the risk based scenario. This was because women with antenatal risk factors were not screened using culture testing in late pregnancy in the model. Reducing the preventive impact of the risk based strategy would not necessarily lead to more cases being prevented by screening.
Therefore, to try to accommodate the concerns which had been raised, an additional analysis was undertaken. This assumed that the rate of EOGBS in term carriers with no risk factors had increased. This is the group of women in which culture screening in late pregnancy would alter management the most.
This analysis was not reported in the manuscript because it applied to only one group of women only and because the inputs for the analysis were not derived in the same way as the others.
A general summary of the concern has been included under the heading 'Public and Patient Involvement' and a description of the additional analysis has been included in the amended manuscript.
In your table of evidence, it appears that the RF indicating IAP are all based on expert opinion, is that correct? This should be clearly highlighted in your limitations.
Response
This has been added to the limitations.
O'Sullivan et al has more recent data on EOGBS that would be useful to update (you cite it in your introduction and the group are part of your expert panel. Why did you not use these data?)
The modelling project was completed before completion of the BPSU / PHE enhanced surveillance study. The results of the enhanced surveillance study were kindly made available for the UK NSC evidence review undertaken by Warwick University Medical School.
See earlier comment.
Reviewer 2: Gopal Rao
Assumptions: The authors of the paper have been selective in their reference to studies used build the model.
Response
The process through which the model inputs were selected was described in the paper. This now includes more information on the level of consensus achieved through the process. 
The 2014/15 enhanced surveillance study was not available at the time of the modelling work. The paper reflects the modelling conducted using inputs agreed through discussions with the expert group, and as such it would be inappropriate to retrospectively change data inputs.
Outside of the conference abstract referenced by the reviewer the BPSU 2014/2015 results remains unpublished at the time of writing.
The results of the study were kindly made available during the development of the UK NSC review of screening in 2016. See the response to the comment above on the study.
A separate analysis was undertaken by the authors to reflect the possibility of an increased EOGBS rate in women with no risk factors.
The manuscript has been amended to describe this scenario.
2. While the authors have referred to the new RCOG guidelines that appeared in 2017, they have also failed to acknowledge two observational studies of screening were published in the BMJ Open in 2017, which are the only published reports of a screening programme, its design, implementation and outcome. The first paper, reports a substantial fall in EOGBS rates following GBS screening and intrapartum antimicrobial prophylaxis of the carriers of GBS. The paper also provides rates of GBS colonization in different ethnic groups. The second study reported on rise in rates in early onset GBS infection after cessation of the screening programme. While RCTs are considered as the gold standard, to ignore these observational studies (albeit in a single centre) in preference to systematic reviews and metanalysis of trials not necessarily undertaken in the UK, is to sacrifice the good at the alter of the seemingly perfect. It is accepted that the RCOG guideline mentioned in the discussion was published following completion of the modelling project. This was mentioned in the manuscript to clarify that the risk groups which are eligible for IAP in the UK had changed since the modelling project was completed and that clindamycin was no longer recommended as a second line antibiotic. It did not change inputs to the model.
The papers on the Northwick Park experience were also published following completion of the modelling project. The manuscript reflects the modelling conducted using inputs agreed through discussions with the expert group, and as such it would be inappropriate to retrospectively change data inputs without re-convening the expert group. This would need to be the subject of a follow up project.
In addition some of the values reported in the newer papers mentioned are already within the ranges included within the model. For example:
• Colonisation rate in the model is 22% (sensitivity analyses 20% and 30%). In the newer papers it was reported as 29.4% when recto vaginal swabs were considered.
• Screening uptake in the model is 90% (sensitivity analyses 75% and 95%). In the newer papers it was reported as 69% for the period as a whole and 75% for 2015.
• Proportion of screen positive women receiving IAP in the model is 80% (sensitivity analyses 70% and 90%). In the newer papers it was reported as 80.7%.
Furthermore, the referenced papers concluded that the results may not be generalisable to other units in the UK. The published discussion stimulated by the papers draws attention to the possibility of a large RCT of culture based screening taking place in the UK. This will provide a more significant point of departure for future estimates of the preventive impact of screening.
(https://bmjopen.bmj.com/content/7/4/e014634.responses)
For these reasons we think that further reconsideration of the model's parameters on the basis of the papers is not justified at the current time.
3. In my opinion, in addition to above many key papers have been ignored while others have been selectively cited to inform the modelling and the discussion. These include a. Daniels et al. (ref 30, 43) found PCR far more sensitive (84 versus 30% [25-35%] ) and specific (87 versus 80% [77-82%]) than risk factor-based screening (P < 0.001). The gold standard used was intrapartum culture of vaginal and rectal swabs. Furthermore number of women needing IAP was similar for both risk based and screening positive groups. This runs counter to the results of the modelling. Thus the key determinant for difference in number of women offered IAP will be the PPV and NPV between antenatal and intrapartum cultures.
The comparison drawn by the reviewer is not one made by the model (ie PCR based screening alone vs risk based assessment alone).
The model only assessed the use of culture-based screening, and not PCR-based screening. In addition, as explained in our comments above, the strategies compared are:
• Risk based assessment alone
• Risk based assessment PLUS culture based antenatal screening for women without risk factors indicating IAP.
The referenced Daniels et al paper reports the proportion of the study population with the following risk factors:
• Preterm labour
• PROM >18hours
• Previous baby with GBS disease
• Maternal fever
• Incidentally detected GBS in the current pregnancy
These accounted for 22.1% of the study population. As stated by the reviewer, this is virtually identical to the maternal colonisation rate of 22% used in the model. Therefore the rates of IAP could be similar if these antenatal and intrapartum risk factors were all indications for IAP at the time of the modelling exercise.
However the modelled strategy for IAP in the women with risk factors followed that of the 2012 RCOG guideline. This guideline did not recommend IAP for all women in preterm labour or with PROM >18 hours.
The model also assumed that not all women who were eligible for IAP received it (in either scenario). Uptake rates were agreed by the expert group.
This meant that the proportion of women both eligible for and receiving IAP on the basis of risk factors was lower than 22.1%.
The combined screening and risk factor strategy in the model did not reduce the rate of IAP in the risk groups. This was because women eligible for IAP on the basis of the relevant antenatal risk factors were not eligible for culture based screening in late pregnancy. As such IAP in the screen positive women was additional to that in the women with risk factors. We think this approach is consistent with screening practice internationally. This is not to say that a strategy of screening women with existing risk factors for EOGBS in late pregnancy could not be developed but it was not the approach agreed by the expert group. In the Northwick Park paper (Gopal Rao G , Nartey G , McAree T , et al . BMJ Open 2017; 7:e014634.doi:10.1136 /bmjopen-2016 women with antenatal risk factors were offered screening in late pregnancy. However those identified as at risk because of, for example, GBS bacteriuria or a previous baby affected by GBS remained eligible for IAP even if the GBS screening test at 35 -37 weeks was negative. Even here IAP eligibility was not directed by the screening test in the risk groups.
b. Valkenberg et al (ref 25) reported "Positive predictive values for antenatal GBS cultures ranged from 43 to 100% (mean 69%) and negative predictive values from 80 to 100% (mean 94%). GBS cultures collected in late pregnancy had high positive predictive values for colonization during delivery. The negative predictive value was high and relatively constant regardless of GA.
Conclusions: This systematic review confirms recommendations to screen pregnant women for colonization of GBS at 35-37 weeks' gestation, but one should be aware of the limitations of screening, with 6% of GBS carriers remaining undetected in antenatal cultures." Given differences in methods used and prevalence of GBS in the studies reviewed in the systematic analysis, transition rates between antenatal and intranatal carriage should be reassessed using optimal culture methods as described by SMI B58 of Public health England. A true rate will make an important difference to modelling outcomes.
The transition rates for maternal colonisation status between the point of screening and term labour were the subject of sensitivity analysis. 
In relation to anaphylaxis, the rate of penicillin anaphylaxis used in the model was 1.56 / 100,000. The authors of the referenced paper suggested that further research would improve understanding of this issue.
However, application of this rate resulted in 0.3 cases / year in the risk factor arm of the model.
A UK study has subsequently reported one case of anaphylaxis in a woman who received penicillin IAP for EOGBS. (McCall SJ et al, The incidence, characteristics, management and outcomes of anaphylaxis in pregnancy: a population-based descriptive study, BJOG 2018 Jul; 125(8): 965-971) This was over a three year period in a setting with no universal screening for GBS and, as stated above, a limited number of risk factors providing indications for IAP. Unfortunately no information on the total number of women receiving GBS IAP in this period was reported so no denominator is available. The model's estimate of 0.3 cases / year in the risk factor scenario is consistent with this report at least as a numerator.
We appreciate the reviewer's concerns about this parameter. While penicillin anaphylaxis was noted as an 'extremely rare event' and no further point was made, an additional comment has been added to the current sentence.
In relation to the proportion of women reporting allergy to penicillin again we appreciate the reviewer's concern about uncertainty on this parameter. We have added a reference to this in the limitations section of the manuscript.
d. The authors also raise the issue of antimicrobial resistance and stewardship. While not disputing the importance of antimicrobial resistance and stewardship, the rarity of penicillin (narrow spectrum antibiotic) resistance in GBS is understated in the paper. Furthermore, the authors should clarify that all reported cases of reduced susceptibility of GBS strains to penicillin have been isolated from elderly patients receiving penicillin for respiratory illness. ( Kimura, et al 2006. Emergence of penicillinresistant group B streptococci. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C2-1286.) To my knowledge, penicillin tolerant strains have not been reported from babies with EOGBS infection or maternal carriers despite more than two decades of penicillin based IAP. Thus it appears that the issue of resistance has been overemphasized.
The concern referred to in the manuscript was raised by the authors of the relevant papers. An amendment has been made to the sentence referring to isolates with reduced susceptibility to reflect this and their rarity.
Interestingly, publications which report small numbers isolates from pregnant women which are resistant to penicillin or have reduced susceptibility are available:
Huang J et al, Alarming regional differences in prevalence and antimicrobial susceptibility of group B streptococci in pregnant women: A systematic review and meta-analysis, Journal of Global Antimicrobial Resistance, 7 (2016) We do not know whether confirmatory analysis has been undertaken to determine whether these were true or false positive reports. But examples have been published.
An aim of the Antimicrobial Resistance Strategy is to reduce inappropriate antibiotic prescriptions. The modelled strategies suggest that antenatal screening would expand the IAP into a low risk population, while not reducing IAP in the groups defined by antenatal risk factors, therefore the rate of overtreatment is the focus.
e. Effect of IAP on infant faecal microbiome and its impact on child development is still unclear.
Incidentally there appears to be greater impact of IAP (broad spectrum antibiotics) given for cesarean sections (in 25-30% mothers) than that given for EOGBS.
We agree that the impact of GBS IAP on child development is unclear and think this is reflected in the manuscript.
This manuscript has dealt with IAP for GBS and comparison with other indications for use was not part of the model's remit.
Methodology used: Expert Group Consensus Given that many of the members of the expert panel have held previously stated views regarding risk based or screening strategies, it would be transparent if the authors state which of the assumptions and publications used for modelling had 75% and those that had more than > 50% agreement. I believe that >50% would not generally be regarded as 'consensus'.
More detail on this has been provided in the revised manuscript.
See the response to the comment above. We are unable to comment on whether the enhanced surveillance data can be used to evaluate the performance of the risk based strategy.
However an additional analysis of an increased rate of EOGBS in the term women with no risk factors has been reported in the revised manuscript. The main aim of the model was to explore the additional number of women who may need to be treated with IAP to prevent additional EOGBS cases and deaths when culture screening is added to a risk factor based approach, based on the evidence that was available at the time.
In this regard use of the enhanced surveillance data has been addressed for the main group of interest in the model.
We hope the responses to the comments have addressed this concern. We wish to emphasise that the model's development was informed by the selection of inputs guided by an expert group which included all perspectives in the debate on antenatal screening.
The inclusion of the information on the level of agreement on the inputs suggests that there was a great deal of consensus on these.
Reviewer 3: Prof. Giampiero Capobianco,
The topic is interesting and the manuscript is well written.
Many thanks for this comment.
Reviewer 4: Julie Morris Institution and Country: UHSM, UK This paper reports on the work of a multi-disciplinary expert group set up to estimate the effect of adding screening for GBS at 35-37 weeks of pregnancy to the current recommended risk-based prevention policy. The impact on the use of IAP, early onset GBS and EOGBS mortality is considered using data derived from deterministic modelling, which is a reasonable and simple statistical approach to the problem.
Many thanks for this comment on the approach to the modelling.
1. At present, the methodology of the modelling process is difficult to understand and follow through. It might help to have the two supplementary Figures 1 and 2 , as main Figures in the paper.
We have included the figures in the main manuscript.
2. The modelling estimates of the outcomes are heavily dependent on the estimates of the parameters. This is acknowledged by the researchers, and a limited 'sensitivity analysis' is carried out by considering a range of values for four of the parameters. However, it would be useful to extend this to some of the more influential parameters in the model, and to report how this might affect the results.
We have added a discussion of an additional analysis undertaken following discussion with the expert group when the model results were circulated.
This reflects the possibility of an increased EOGBS rate in term carriers with no risk factors indicating IAP. This was prompted by the results of an enhanced UK wide surveillance study which was competed after the modelling project.
See responses to comments from reviewers 1 & 2.
The figure has been replaced by a table of results.
We have amended the sentence and reviewed the manuscript as a whole.
Reviewer 5: Katharine Correia Institution and Country: Department of Mathematics and Statistics, Amherst College, USA This paper reports on a modelling study designed to estimate the potential impact of adding culturebased screening for Group B Streptococcus in pregnancy to the existing risk-based prevention policy in the UK. The paper is very well-written. The goal of the paper is well-defined, and the methods are explained clearly.
1. Page 6, Line 9: I was unaware that Microsoft Excel has the capabilities needed to perform a modelling study. Is this done using a point-and-click process, or is there reproducible code which could be provided? It would be helpful if code could be provided in the Supplementary material, such that other researchers could replicate the study, or reproduce the model to extend upon this research.
The Excel model uses simple calculations using the underlying parameters in Excel (e.g. applying subsequent % to funnel women into the individual clinical risk groups, and then applying the rates of EOGBS, the effects of treatment to the rates, and the rates of morbidity and mortality to those affected with EOGBS).
There is no code used (other than e.g. VLOOKUP functions to find the correct data).
2. The authors' method of determining the input parameters and gaining consensus is well laid out. Tables 2-5 are particularly helpful in defining the input parameter values and sources. However, as a statistician with little subject matter knowledge on this topic, I feel I am unable to assess the reasonability of the input parameter values, particularly the many inputs for which the source is listed as "expert group consensus". It is reassuring that a multi-disciplinary stakeholder group contributed to the consensus, but given that, as the authors acknowledge, "the evidence base available for many input parameters is limited and this may affect the accuracy of the model's predictions":
We agree, and think that this is also an important finding of the process, i.e. that for many parameters good quality evidence is not available,. Hence our statement which you highlight.
a) It would be helpful if a few outside clinical reviewers well-versed in this area could comment on the input parameter values used.
The expert group included multidisciplinary clinical and other stakeholders. See also other reviewer comments.
b) The sensitivity analyses are very important. More clarity on how they were conducted would be helpful. For example, were each of the four input parameters changed one at a time (while keeping all other inputs the same as in the main model) or were multiple parameters changed simultaneously? If simultaneously, how so? The sensitivity values are given in ranges in the Tables -were just those lower and upper bounds assessed, or were additional values in between also considered?
The sensitivity analyses were univariate, i.e. each parameter was changed one at a time, to the upper and lower bounds assessed.
This has been clarified in the text. c) Again, in light of the limited evidence base available for many input parameters, it would be valuable to conduct additional sensitivity analyses, varying additional input parameters (e.g. assess an expanded range for colonisation rates, vary optimal IAP delivery proportions?).
This reflects the possibility of an increased EOGBS rate in term carriers with no risk factors indicating IAP. This was prompted by the results of an enhanced UK wide surveillance study which was completed after the modelling project.
See responses to comments from reviewers 1, 2 & 4 above. d) Daniels et al. (BJOG 2011) report the rate of maternal GBS for their UK cohort at 21%. In Table 2 , the rate of maternal intrapartum infection in term deliveries is specified to be 2.1%. Is this a typo, or am I misunderstanding what rate this corresponds to in the Daniels paper?
